title: Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
abstract: Long-term (3.5 years) immune reconstitution in relation to viral load response was determined. Plasma HIV-1 RNA was suppressed in 40 patients (full responders) up to 42 months, and 17 patients achieved partial response. The measurements of CD4(+) and CD8(+) T lymphocyte subsets (CD45RA, CD45RACD62L, CD45RO, CD28, CD38) were carried out by flow cytometry. Full responders had a significant increase of CD4(+) and all CD4(+) T subsets both up to 6 and from 6 to 42 months, while the increase for partial responders was only up to 6 months. By 6 months, higher slopes were observed in full versus partial responders in the % of CD28 on CD4(+) and the % of CD4(+) memory subset and in both naïve and memory CD4(+) subsets from 6 to 42 months. The percentage of CD8(+) and its subsets was decreased significantly in full responders both up to 6 and from 6 to 42 months (except for an increase in the CD8(+)CD45RA(+) CD62L(+) cells), while in partial responders this decrease was only up to 6 months. Lower slopes were observed in full versus partial responders from 6 to 42 months in the percentages of CD8(+), CD8(+)CD45RO(+), CD8(+)CD28(-), and CD8(+)CD38(+) T cells. In conclusion, full responders have a stronger long-term naive CD4(+) T cell subset reconstitution than partial responders.
authors.affiliation: Department of Immunology, Laiko General Hospital, Athens, Greece. choremi-pap@hotmail.com
authors.forename: H
authors.initials: H
authors.lastname: Choremi-Papadopoulou
authors.forename: K
authors.initials: K
authors.lastname: Tsalimalma
authors.forename: U
authors.initials: U
authors.lastname: Dafni
authors.forename: A
authors.initials: A
authors.lastname: Dimitracopoulou
authors.forename: T
authors.initials: T
authors.lastname: Kordossis
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D000163:Acquired Immunodeficiency Syndrome; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D023241:Antiretroviral Therapy, Highly Active; D018106:CD28 Antigens / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D018791:CD4 Lymphocyte Count; D016827:CD8 Antigens / Q000032:analysis; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D007156:Immunologic Memory; D016130:Immunophenotyping; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D008562:Membrane Glycoproteins; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D016176:T-Lymphocyte Subsets / Q000473:pathology; D019562:Viral Load; D014766:Viremia
chemical_list: D015703:Antigens, CD; D018106:CD28 Antigens; D015704:CD4 Antigens; D016827:CD8 Antigens; D008562:Membrane Glycoproteins; D012367:RNA, Viral; D017493:Leukocyte Common Antigens; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1